Marks R M, Vaccaro A R, Balderston R A, Hozack W J, Booth R E, Rothman R H
Department of Orthopaedic Surgery, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
J Arthroplasty. 1995 Aug;10(4):433-7. doi: 10.1016/s0883-5403(05)80142-1.
One hundred forty-four patients who underwent primary total knee arthroplasty were examined in a prospective controlled study to determine the efficacy and safety of a postoperative wound drainage autotransfusion system (Solcotrans, Smith & Nephew Richards, Memphis, TN). The patients were divided into two groups: control group 1 comprised 88 (61%) patients who either received a Hemovac disposable drainage system (63 patients) or the Solcotrans system and had inadequate drainage for autotransfusion (25 patients). Experimental group 2 comprised 56 (39%) patients who received a Solcotrans drainage system and were autotransfused. The Solcotrans proved itself safe. No sepsis, transfusion reactions, or coagulopathies were associated with autotransfusion, which averaged 524 mL. There were no significant differences between groups 1 and 2 when comparing preoperative and postoperative hemoglobins and hematocrits. The Solcotrans system did not lower homologous blood requirements. Only 1.6% (2 patients) of all patients who autodonated at least 2 units of autologous blood (122 patients) were in need of a homologous blood transfusion in the postoperative period. Thus, although safe, the Solcotrans system was not proven effective in the management of primary total knee arthroplasty patients.
在一项前瞻性对照研究中，对144例行初次全膝关节置换术的患者进行了检查，以确定术后伤口引流自动输血系统（Solcotrans，史赛克理查兹公司，田纳西州孟菲斯）的有效性和安全性。患者被分为两组：对照组1包括88名（61%）患者，他们要么接受了Hemovac一次性引流系统（63名患者），要么接受了Solcotrans系统但引流不足无法进行自动输血（25名患者）。实验组2包括56名（39%）接受Solcotrans引流系统并进行了自动输血的患者。Solcotrans证明了自身的安全性。自动输血平均为524毫升，未出现与自动输血相关的败血症、输血反应或凝血障碍。比较术前和术后血红蛋白及血细胞比容时，1组和2组之间无显著差异。Solcotrans系统并未降低异体血的需求量。在所有至少自体捐献2单位自体血的患者（122名患者）中，只有1.6%（2名患者）在术后需要异体输血。因此，尽管Solcotrans系统安全，但在初次全膝关节置换术患者的管理中未被证明有效。
